Business Context and Reporting Period
Company: TherapeuticsMD, Inc. (TXMD)
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2014 (Event Date: July 30, 2014)
Business Overview: TXMD is a women's health care product company focused on commercializing products for women, including prenatal vitamins, OTC vitamins, and cosmetics. The company is primarily engaged in the clinical development of advanced hormone therapy pharmaceutical products (estradiol and progesterone) to treat menopause-related symptoms. The filing updates disclosures regarding the company's business and provides preliminary financial estimates for the second quarter of 2014.
Key Financial Metrics
Note: The following figures are preliminary estimates for the three months ended June 30, 2014, as final financial statements were not yet available at the time of filing.
| Metric | Q2 2014 (Estimated) | Q2 2013 (Actual) |
|---|---|---|
| Net Revenues | $3.5 million – $3.9 million | $2.1 million |
| Net Loss | $(10.5) million – $(11.3) million | $(6.0) million |
| Net Loss Per Share (Basic & Diluted) | $(0.06) – $(0.08) | $(0.05) |
| Weighted Avg. Shares Outstanding | ~145.5 million | ~130.9 million |
Liquidity and Cash Position:
Cash on hand as of June 30, 2014: Approximately $35.6 million (down from $54.2 million as of December 31, 2013).
Accumulated Deficit (as of March 31, 2014): Approximately $90 million.
Net Operating Loss (NOL) Carryforwards (as of Dec 31, 2013): Approximately $37 million.
Material Changes and Operational Updates
- Revenue Growth: Estimated Q2 2014 revenue represents a significant increase (approximately 67% to 86%) compared to the prior year period, driven by sales of women's health care products.
- Increased Losses: Net loss is expected to widen significantly year-over-year due to increased research, development, and clinical trial activities.
- Cash Burn: Cash reserves decreased by approximately $18.6 million in the first half of 2014.
- Patent Allowance: In July 2014, the company received Notices of Allowance from the U.S. Patent and Trademark Office for two applications related to its combination estradiol/progesterone drug candidate.
- Product Launch: Introduced "vitaPearl" (branded) and "Prena1 Pearl" (generic) prescription prenatal vitamins in Q1 2014, replacing existing formulations.
Guidance, Outlook, and Risks
Clinical Trial Status and Outlook
- TX-001HR (Combination Estradiol/Progesterone): Phase 3 "REPLENISH" trial enrollment is anticipated to complete in Q4 2014, with results expected in Q4 2015.
- TX-002HR (Oral Progesterone): Phase 3 "SPRY" trial enrollment was temporarily suspended in July 2014 to update the protocol following FDA discussions. The company intends to target women with secondary amenorrhea due to polycystic ovarian syndrome.
- TX-004HR (Vaginal Suppository Estradiol): Phase 3 trial intended to begin in Q3 2014. Enrollment expected to complete in Q2 2015, with results in Q3 2015. NDA filing anticipated in Q4 2015.
- Early Development: Plans to file INDs for topical cream (TX-005HR, TX-006HR) and transdermal patch (TX-007HR, TX-008HR) candidates in Q4 2014.
Management Commentary and Strategy
The company aims to penetrate the bioidentical hormone market with FDA-approved products to offer a safer, more consistent alternative to compounded products. The strategy includes expanding sales territories from 36 to 60 within 18 months and maintaining a focus on OB/GYN practices.
Material Risks and Contingencies
- Financing Needs: The company explicitly states that existing cash is insufficient to fund future clinical development and commercialization. Additional financing is required, which may result in dilution or unfavorable terms.
- Clinical Trial Uncertainty: Risks include enrollment delays, protocol changes, failure to demonstrate efficacy/safety, and potential FDA rejection of NDAs.
- Regulatory and Legal: Risks related to FDA regulations, product liability lawsuits, intellectual property disputes, and compliance with healthcare fraud laws.
- Third-Party Dependence: Reliance on third-party manufacturers (e.g., Lang Pharma for 98% of vitaMedMD products) and Contract Research Organizations (CROs) for clinical trials.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to secure additional financing given the $35.6 million cash balance and projected continued losses.
- Clinical Trial Timelines: Monitor the resumption and progress of the suspended TX-002HR (SPRY) trial and the initiation of the TX-004HR trial.
- Revenue Sustainability: Assess the durability of the revenue growth in the vitamin/supplement segment, which currently funds operations.
- Regulatory Milestones: Track FDA feedback on the updated TX-002HR protocol and the acceptance of future INDs for topical/patch candidates.
- Patent Portfolio: Confirm the issuance of the two recently allowed patents and their scope of protection.